AFT Pharmaceuticals Limited

AFT

NZAFTE0001S4

Pharmaceuticals

End-of-day quote New Zealand S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.09 ^NZD	+0.65%		-1.59%	-11.71%

Apr. 24	New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment	MT
Apr. 24	AFT Pharmaceuticals, Massey Ventures, Gillies McIndoe Research Institute Partner to Develop Topical Scar Treatment	MT

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

November 22, 2023 at 04:00 pm EST

AFT Pharmaceuticals Limited reaffirmed earnings guidance for the fiscal year 2024. The company is continuing with its operating profit guidance of $22 million to $24 million.

Latest news about AFT Pharmaceuticals Limited

New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment	Apr. 24	MT
AFT Pharmaceuticals, Massey Ventures, Gillies McIndoe Research Institute Partner to Develop Topical Scar Treatment	Apr. 24	MT
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down	Mar. 03	MT
AFT Pharmaceuticals to Expand Global Footprint with Signing of Supply, Production Deals	Mar. 03	MT
Aft Expands Its Co-Operation with Hikma Pharmaceuticals	Mar. 03	CI
New Zealand Shares Rebound on Friday Close; AFT Pharmaceuticals Raises Operation Profit Guidance	Feb. 15	MT
AFT Pharmaceuticals Boosts Operating Profit Guidance for Fiscal Year 2024	Feb. 15	MT
AFT Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024	Feb. 15	CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4%	Feb. 06	MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US	Feb. 05	MT
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication	Jan. 18	MT
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus	Jan. 18	CI
AFT Pharmaceuticals Ties Up with Hyloris to Develop Burning Mouth Syndrome Treatment Candidate	Dec. 21	MT
AFT Pharmaceuticals Limited Enters into Partnership with Hyloris Pharmaceuticals	Dec. 21	CI
France keeps 2024 bond issuance steady at 285 bln euros	Dec. 13	RE
AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024	Nov. 22	CI
Transcript : AFT Pharmaceuticals Limited, H1 2024 Earnings Call, Nov 23, 2023	Nov. 22
AFT Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 22	CI
AFT Pharmaceuticals Secures Clearance to Sell Antiseptic Ointment in China	Nov. 21	MT
Hyloris Pharma wins US FDA approval for pain treatment	23-10-18	RE
AFT Pharmaceuticals Secures US FDA Approval for Sale of Intravenous Pain Relief Drug	23-10-18	MT
AFT Pharmaceuticals Limited Announces Retirement of Jon Lamb as New Independent Director	23-09-27	CI
AFT Pharmaceuticals Announces Board Changes	23-09-27	CI
Transcript : AFT Pharmaceuticals Limited - Shareholder/Analyst Call	23-08-03
AFT Pharmaceuticals Secures Australia, New Zealand License for Epilepsy Rescue Medication	23-07-20	MT

Chart AFT Pharmaceuticals Limited

Duration

Period

More charts

AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.

Sector

Pharmaceuticals

Calendar

2024-05-21 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for AFT Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.09 NZD

Average target price

3.7 NZD

Spread / Average Target

+19.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AFT PHARMACEUTICALS LIMITED	-11.71%	192M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals